User login
, according to manufacturer Verona Pharma.
Ensifentrine offers a new medication and a new delivery method, according to a company press release. Ensifentrine is the first-in-class selective dual inhibitor of both phosphodiesterase 3 (PDE 3) and PDE 4, combining both bronchodilator and nonsteroidal anti-inflammatory effects in a single molecule. The drug is delivered through a standard jet nebulizer.
Disease Management Made Easier
Although currently approved therapies for COPD, such as bronchodilators and inhaled corticosteroids (ICS), have benefited many patients, additional treatment options are still needed to help those who remain symptomatic and suffer from frequent exacerbations, said Diego J. Maselli, MD, of the University of Texas Health Science Center, San Antonio.
“Ensifentrine is a new class of medication that inhibits both PDE 3 and PDE 4; this results in both bronchodilation and suppression of the inflammatory response in COPD,” said Dr. Maselli, who was not involved in studies of ensifentrine.
“Large phase III, double-blind, randomized, placebo-controlled studies have demonstrated that ensifentrine improved lung function and reduced the risk of exacerbations in patients with symptomatic moderate to severe COPD,” he said. The study participants were on no long-acting maintenance therapy, or they were receiving long-acting beta agonist (LABA) or long-acting muscarinic antagonist (LAMA) with or without inhaled corticosteroids, he noted.
The FDA approval was supported by data from the phase 3 ENHANCE 1 and 2 trials, which included 760 and 789 adults aged 40-80 years with moderate to severe symptomatic COPD, respectively. Participants were randomized to 3 mg ensifentrine delivered via nebulizer or a placebo twice daily.
In the studies, ensifentrine significantly improved lung function based on the primary outcome of average forced expiratory volume per second within 0-12 hours of administration compared with placebo in both studies. In ENHANCE 1, ensifentrine significantly improved symptoms and quality of life compared with placebo at 24 weeks. The ENHANCE 2 results showed similar trends in favor of ensifentrine, although the differences were not significant at 24 weeks. However, the effects of ensifentrine vs placebo were consistent overall across all symptom and quality of life endpoints at all assessments during the study period, the researchers wrote.
In addition, the inhaled drug was well tolerated, with similar proportions of ensifentrine and placebo patients reporting treatment-emergent adverse events (38.4% and 36.4%, respectively, in ENHANCE 1 and 35.3% and 35.4%, respectively, in ENHANCE 2). The most common treatment-emergent adverse events were nasopharyngitis, hypertension, and back pain, reported in < 3% of the ensifentrine group.
The safety profile of ensifentrine is a plus for patients, said Dr. Maselli. “Ensifentrine was well tolerated in these studies, and the side effect profile was similar to placebo,” he said. The “ensifentrine is delivered via nebulizer and dosed every 12 hours. Some patients may still prefer the use of inhalers, while others may feel more comfortable with this mode of delivery,” he said.
In clinical practice, “ensifentrine is a welcome addition to the current armamentarium of therapies for COPD as an option for patients who are symptomatic or who have frequent exacerbations,” Dr. Maselli emphasized.
Looking ahead, more studies are needed to evaluate ensifentrine in broader populations of COPD patients, Dr. Maselli said. For example, ensifentrine could be used as an add-on therapy for patients receiving triple therapy (ICS/LABA/LAMA) and for patients with other obstructive inflammatory diseases such as asthma, bronchiectasis, and cystic fibrosis, he noted.
Dr. Maselli disclosed serving as a consultant for GlaxoSmithKline, AstraZeneca, Amgen, and Sanofi/Regeneron; he also serves on the Editorial Board of CHEST Physician.
A version of this article appeared on Medscape.com.
, according to manufacturer Verona Pharma.
Ensifentrine offers a new medication and a new delivery method, according to a company press release. Ensifentrine is the first-in-class selective dual inhibitor of both phosphodiesterase 3 (PDE 3) and PDE 4, combining both bronchodilator and nonsteroidal anti-inflammatory effects in a single molecule. The drug is delivered through a standard jet nebulizer.
Disease Management Made Easier
Although currently approved therapies for COPD, such as bronchodilators and inhaled corticosteroids (ICS), have benefited many patients, additional treatment options are still needed to help those who remain symptomatic and suffer from frequent exacerbations, said Diego J. Maselli, MD, of the University of Texas Health Science Center, San Antonio.
“Ensifentrine is a new class of medication that inhibits both PDE 3 and PDE 4; this results in both bronchodilation and suppression of the inflammatory response in COPD,” said Dr. Maselli, who was not involved in studies of ensifentrine.
“Large phase III, double-blind, randomized, placebo-controlled studies have demonstrated that ensifentrine improved lung function and reduced the risk of exacerbations in patients with symptomatic moderate to severe COPD,” he said. The study participants were on no long-acting maintenance therapy, or they were receiving long-acting beta agonist (LABA) or long-acting muscarinic antagonist (LAMA) with or without inhaled corticosteroids, he noted.
The FDA approval was supported by data from the phase 3 ENHANCE 1 and 2 trials, which included 760 and 789 adults aged 40-80 years with moderate to severe symptomatic COPD, respectively. Participants were randomized to 3 mg ensifentrine delivered via nebulizer or a placebo twice daily.
In the studies, ensifentrine significantly improved lung function based on the primary outcome of average forced expiratory volume per second within 0-12 hours of administration compared with placebo in both studies. In ENHANCE 1, ensifentrine significantly improved symptoms and quality of life compared with placebo at 24 weeks. The ENHANCE 2 results showed similar trends in favor of ensifentrine, although the differences were not significant at 24 weeks. However, the effects of ensifentrine vs placebo were consistent overall across all symptom and quality of life endpoints at all assessments during the study period, the researchers wrote.
In addition, the inhaled drug was well tolerated, with similar proportions of ensifentrine and placebo patients reporting treatment-emergent adverse events (38.4% and 36.4%, respectively, in ENHANCE 1 and 35.3% and 35.4%, respectively, in ENHANCE 2). The most common treatment-emergent adverse events were nasopharyngitis, hypertension, and back pain, reported in < 3% of the ensifentrine group.
The safety profile of ensifentrine is a plus for patients, said Dr. Maselli. “Ensifentrine was well tolerated in these studies, and the side effect profile was similar to placebo,” he said. The “ensifentrine is delivered via nebulizer and dosed every 12 hours. Some patients may still prefer the use of inhalers, while others may feel more comfortable with this mode of delivery,” he said.
In clinical practice, “ensifentrine is a welcome addition to the current armamentarium of therapies for COPD as an option for patients who are symptomatic or who have frequent exacerbations,” Dr. Maselli emphasized.
Looking ahead, more studies are needed to evaluate ensifentrine in broader populations of COPD patients, Dr. Maselli said. For example, ensifentrine could be used as an add-on therapy for patients receiving triple therapy (ICS/LABA/LAMA) and for patients with other obstructive inflammatory diseases such as asthma, bronchiectasis, and cystic fibrosis, he noted.
Dr. Maselli disclosed serving as a consultant for GlaxoSmithKline, AstraZeneca, Amgen, and Sanofi/Regeneron; he also serves on the Editorial Board of CHEST Physician.
A version of this article appeared on Medscape.com.
, according to manufacturer Verona Pharma.
Ensifentrine offers a new medication and a new delivery method, according to a company press release. Ensifentrine is the first-in-class selective dual inhibitor of both phosphodiesterase 3 (PDE 3) and PDE 4, combining both bronchodilator and nonsteroidal anti-inflammatory effects in a single molecule. The drug is delivered through a standard jet nebulizer.
Disease Management Made Easier
Although currently approved therapies for COPD, such as bronchodilators and inhaled corticosteroids (ICS), have benefited many patients, additional treatment options are still needed to help those who remain symptomatic and suffer from frequent exacerbations, said Diego J. Maselli, MD, of the University of Texas Health Science Center, San Antonio.
“Ensifentrine is a new class of medication that inhibits both PDE 3 and PDE 4; this results in both bronchodilation and suppression of the inflammatory response in COPD,” said Dr. Maselli, who was not involved in studies of ensifentrine.
“Large phase III, double-blind, randomized, placebo-controlled studies have demonstrated that ensifentrine improved lung function and reduced the risk of exacerbations in patients with symptomatic moderate to severe COPD,” he said. The study participants were on no long-acting maintenance therapy, or they were receiving long-acting beta agonist (LABA) or long-acting muscarinic antagonist (LAMA) with or without inhaled corticosteroids, he noted.
The FDA approval was supported by data from the phase 3 ENHANCE 1 and 2 trials, which included 760 and 789 adults aged 40-80 years with moderate to severe symptomatic COPD, respectively. Participants were randomized to 3 mg ensifentrine delivered via nebulizer or a placebo twice daily.
In the studies, ensifentrine significantly improved lung function based on the primary outcome of average forced expiratory volume per second within 0-12 hours of administration compared with placebo in both studies. In ENHANCE 1, ensifentrine significantly improved symptoms and quality of life compared with placebo at 24 weeks. The ENHANCE 2 results showed similar trends in favor of ensifentrine, although the differences were not significant at 24 weeks. However, the effects of ensifentrine vs placebo were consistent overall across all symptom and quality of life endpoints at all assessments during the study period, the researchers wrote.
In addition, the inhaled drug was well tolerated, with similar proportions of ensifentrine and placebo patients reporting treatment-emergent adverse events (38.4% and 36.4%, respectively, in ENHANCE 1 and 35.3% and 35.4%, respectively, in ENHANCE 2). The most common treatment-emergent adverse events were nasopharyngitis, hypertension, and back pain, reported in < 3% of the ensifentrine group.
The safety profile of ensifentrine is a plus for patients, said Dr. Maselli. “Ensifentrine was well tolerated in these studies, and the side effect profile was similar to placebo,” he said. The “ensifentrine is delivered via nebulizer and dosed every 12 hours. Some patients may still prefer the use of inhalers, while others may feel more comfortable with this mode of delivery,” he said.
In clinical practice, “ensifentrine is a welcome addition to the current armamentarium of therapies for COPD as an option for patients who are symptomatic or who have frequent exacerbations,” Dr. Maselli emphasized.
Looking ahead, more studies are needed to evaluate ensifentrine in broader populations of COPD patients, Dr. Maselli said. For example, ensifentrine could be used as an add-on therapy for patients receiving triple therapy (ICS/LABA/LAMA) and for patients with other obstructive inflammatory diseases such as asthma, bronchiectasis, and cystic fibrosis, he noted.
Dr. Maselli disclosed serving as a consultant for GlaxoSmithKline, AstraZeneca, Amgen, and Sanofi/Regeneron; he also serves on the Editorial Board of CHEST Physician.
A version of this article appeared on Medscape.com.